HIVID Drug Patent Profile

✉ Email this page to a colleague

When do Hivid patents expire, and when can generic versions of Hivid launch?

Hivid is a drug marketed by Roche and is included in one NDA.

The generic ingredient in HIVID is zalcitabine. Additional details are available on the zalcitabine profile page.

Summary for HIVID

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	116
Patent Applications:	4,232
Formulation / Manufacturing:	see details
DailyMed Link:	HIVID at DailyMed

Drug patent expirations by year for HIVID

Anatomical Therapeutic Chemical (ATC) Classes for HIVID

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for HIVID

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for HIVID

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992	⤷ Try a Trial	⤷ Try a Trial
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992	⤷ Try a Trial	⤷ Try a Trial
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-002	Jun 19, 1992	⤷ Try a Trial	⤷ Try a Trial
Roche	HIVID	zalcitabine	TABLET;ORAL	020199-001	Jun 19, 1992	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for HIVID

See the table below for patents covering HIVID around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Australia	616427		⤷ Try a Trial
Australia	2234588		⤷ Try a Trial
Canada	1277915	INHIBITION DU POUVOIR INFECTANT IN VITRO ET DE L'EFFET CYTOPATHOGENE DU HTLV-III/LAV PAR LE 2'3'-DIDESOXYCYTIDINE (INHIBITION OF IN VITRO INFECTIVITY AND CYTOPATHIC EFFECT OF HTLV-III/LAV BY 2'3' -DIDEOXYCYTIDINE)	⤷ Try a Trial
Canada	1334166	PREPARATION ANTIVIRALE CONTENANT DES DIDESOXYNUCLEOSIDES (ANTIVIRAL PREPARATION CONTAINING DIDEOXY-NUCLEOSIDES)	⤷ Try a Trial
Philippines	24796	A METHOD OF PREVENTING AIDS BY USING A DIDIOXYNUCLEOSIDE ANALOG	⤷ Try a Trial
Japan	S6483020	MEDICINAL COMPOSITION FOR PREVENTING OR TREATING AIDS	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for HIVID

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0216511	94C0015	Belgium	⤷ Try a Trial	PRODUCT NAME: GADODIAMIDE; NAT. REGISTRATION NO/DATE: NL 19253 19940425; FIRST REGISTRATION: GB - 0637/0015 19920925
0216511	SPC/GB95/003	United Kingdom	⤷ Try a Trial	SPC/GB95/003:, EXPIRES: 20070406
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for HIVID

Anatomical Therapeutic Chemical (ATC) Classes for HIVID

Make Better Decisions: Try a trial or see plans & pricing